{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:30:57Z","timestamp":1792618257827,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07658-x","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T07:23:13Z","timestamp":1770621793000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Engineered exosomes from umbilical cord mesenchymal stem cells with pPB modification attenuate hepatic fibrosis via hepatic stellate cell targeting"],"prefix":"10.1186","volume":"24","author":[{"given":"Fanghong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongbin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxia","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoliang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanghui","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"7658_CR1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nri3169","volume":"12","author":"U Protzer","year":"2012","unstructured":"Protzer U, Maini MK, Knolle PA. Living in the liver: hepatic infections. Nat Rev Immunol. 2012;12:201\u201313.","journal-title":"Nat Rev Immunol"},{"key":"7658_CR2","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","volume":"9","author":"H Hagstr\u00f6m","year":"2024","unstructured":"Hagstr\u00f6m H, Shang Y, Hegmar H, Nasr P. Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Lancet Gastroenterol Hepatol. 2024;9:944\u201356.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"7658_CR3","doi-asserted-by":"publisher","first-page":"122028","DOI":"10.1016\/j.biomaterials.2023.122028","volume":"295","author":"Y Wang","year":"2023","unstructured":"Wang Y, Liu Y, Liu Y, Zhong J, Wang J, Sun L, Yu L, Wang Y, Li Q, Jin W, Yan Z. Remodeling liver microenvironment by L-arginine loaded hollow polydopamine nanoparticles for liver cirrhosis treatment. Biomaterials. 2023;295:122028.","journal-title":"Biomaterials"},{"key":"7658_CR4","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.jhep.2023.06.018","volume":"79","author":"S Verma","year":"2023","unstructured":"Verma S, Hingwala J, Low JTS, Patel AA, Verma M, Bremner S, Haddadin Y, Shinall MC, Komenda P, Ufere NN. Palliative clinical trials in advanced chronic liver disease: challenges and opportunities. J Hepatol. 2023;79:1236\u201353.","journal-title":"J Hepatol"},{"key":"7658_CR5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S2468-1253(18)30244-9","volume":"4","author":"FM Thompson","year":"2019","unstructured":"Thompson FM, Ferguson JW, Kelly DA, Hirschfield GM. Liver disease in the young adult: the challenges and rewards. Lancet Gastroenterol Hepatol. 2019;4:248\u201354.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"7658_CR6","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1136\/gutjnl-2014-306842","volume":"64","author":"YA Lee","year":"2015","unstructured":"Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut. 2015;64:830\u201341.","journal-title":"Gut"},{"key":"7658_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1186\/s13287-020-01895-1","volume":"11","author":"C Hu","year":"2020","unstructured":"Hu C, Zhao L, Zhang L, Bao Q, Li L. Mesenchymal stem cell-based cell-free strategies: safe and effective treatments for liver injury. STEM Cell Res Ther. 2020;11:377.","journal-title":"STEM Cell Res Ther"},{"key":"7658_CR8","doi-asserted-by":"publisher","first-page":"1096402","DOI":"10.3389\/fimmu.2022.1096402","volume":"13","author":"P Liu","year":"2022","unstructured":"Liu P, Qian Y, Liu X, Zhu X, Zhang X, Lv Y, Xiang J. Immunomodulatory role of mesenchymal stem cell therapy in liver fibrosis. Front Immunol. 2022;13:1096402.","journal-title":"Front Immunol"},{"key":"7658_CR9","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1631\/jzus.B1600101","volume":"17","author":"Y Guo","year":"2016","unstructured":"Guo Y, Chen B, Chen LJ, Zhang CF, Xiang C. Current status and future prospects of mesenchymal stem cell therapy for liver fibrosis. J Zhejiang Univ Sci B. 2016;17:831\u201341.","journal-title":"J Zhejiang Univ Sci B"},{"key":"7658_CR10","doi-asserted-by":"publisher","first-page":"e346","DOI":"10.1038\/emm.2017.63","volume":"49","author":"G Lou","year":"2017","unstructured":"Lou G, Chen Z, Zheng M, Liu Y. Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases. Exp Mol Med. 2017;49:e346.","journal-title":"Exp Mol Med"},{"key":"7658_CR11","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s12072-024-10717-y","volume":"18","author":"R Zong","year":"2024","unstructured":"Zong R, Zheng Y, Yan Y, Sun W, Kong L, Huang Y, Liu Y, Jiang C, Ping J, Li C. Mesenchymal stem cells-derived exosomes alleviate liver fibrosis by targeting Hedgehog\/SMO signaling. Hepatol Int. 2024;18:1781\u201391.","journal-title":"Hepatol Int"},{"key":"7658_CR12","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1089\/scd.2012.0395","volume":"22","author":"T Li","year":"2013","unstructured":"Li T, Yan Y, Wang B, Qian H, Zhang X, Shen L, Wang M, Zhou Y, Zhu W, Li W, Xu W. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. STEM Cells Dev. 2013;22:845\u201354.","journal-title":"STEM Cells Dev"},{"key":"7658_CR13","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1021\/acsabm.2c00246","volume":"5","author":"S Baek","year":"2022","unstructured":"Baek S, Jeon M, Jung HN, Lee W, Hwang JE, Lee JS, Choi Y, Im HJ. M1 macrophage-derived exosome-mimetic Nanovesicles with an enhanced Cancer targeting ability. ACS Appl Bio Mater. 2022;5:2862\u201369.","journal-title":"ACS Appl Bio Mater"},{"key":"7658_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jare.2021.01.001","volume":"31","author":"N Parada","year":"2021","unstructured":"Parada N, Romero-Trujillo A, Georges N, Alcayaga-Miranda F. Camouflage strategies for therapeutic exosomes evasion from phagocytosis. J Adv Res. 2021;31:61\u201374.","journal-title":"J Adv Res"},{"key":"7658_CR15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3350\/cmh.2024.0022","volume":"30","author":"J Qu","year":"2024","unstructured":"Qu J, Wang L, Li Y, Li X. Liver sinusoidal endothelial cell: an important yet often overlooked player in the liver fibrosis. Clin Mol Hepatol. 2024;30:303\u201325.","journal-title":"Clin Mol Hepatol"},{"key":"7658_CR16","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.2147\/IJN.S450284","volume":"19","author":"D Zhu","year":"2024","unstructured":"Zhu D, Sun Z, Wei J, Zhang Y, An W, Lin Y, Li X. BMP7-loaded human umbilical cord mesenchymal stem cell-derived small extracellular Vesicles ameliorate liver fibrosis by targeting activated hepatic stellate cells. Int J Nanomed. 2024;19:3475\u201395.","journal-title":"Int J Nanomed"},{"key":"7658_CR17","doi-asserted-by":"publisher","first-page":"e008737","DOI":"10.1161\/JAHA.118.008737","volume":"7","author":"X Wang","year":"2018","unstructured":"Wang X, Chen Y, Zhao Z, Meng Q, Yu Y, Sun J, Yang Z, Chen Y, Li J, Ma T, et al. Engineered exosomes with ischemic myocardium-targeting peptide for targeted therapy in myocardial infarction. J Am Heart Assoc. 2018;7:e008737.","journal-title":"J Am Heart Assoc"},{"key":"7658_CR18","doi-asserted-by":"publisher","first-page":"119616","DOI":"10.1016\/j.biomaterials.2019.119616","volume":"230","author":"QQ Fan","year":"2020","unstructured":"Fan QQ, Zhang CL, Qiao JB, Cui PF, Xing L, Oh YK, Jiang HL. Extracellular matrix-penetrating nanodrill micelles for liver fibrosis therapy. Biomaterials. 2020;230:119616.","journal-title":"Biomaterials"},{"key":"7658_CR19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jconrel.2011.12.023","volume":"159","author":"F Li","year":"2012","unstructured":"Li F, Li QH, Wang JY, Zhan CY, Xie C, Lu WY. Effects of interferon-gamma liposomes targeted to platelet-derived growth factor receptor-beta on hepatic fibrosis in rats. J Control Release. 2012;159:261\u201370.","journal-title":"J Control Release"},{"key":"7658_CR20","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1002\/j.1460-2075.1991.tb04988.x","volume":"10","author":"JM Clements","year":"1991","unstructured":"Clements JM, Bawden LJ, Bloxidge RE, Catlin G, Cook AL, Craig S, Drummond AH, Edwards RM, Fallon A, Green DR, et al. Two PDGF-B chain residues, arginine 27 and isoleucine 30, mediate receptor binding and activation. Embo J. 1991;10:4113\u201320.","journal-title":"Embo J"},{"key":"7658_CR21","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/S0006-2952(03)00445-3","volume":"66","author":"L Beljaars","year":"2003","unstructured":"Beljaars L, Weert B, Geerts A, Meijer DK, Poelstra K. The preferential homing of a platelet derived growth factor receptor-recognizing macromolecule to fibroblast-like cells in fibrotic tissue. Biochem Pharmacol. 2003;66:1307\u201317.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"7658_CR22","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41565-020-00836-6","volume":"16","author":"M Hu","year":"2021","unstructured":"Hu M, Wang Y, Liu Z, Yu Z, Guan K, Liu M, Wang M, Tan J, Huang L. Hepatic macrophages act as a central hub for relaxin-mediated alleviation of liver fibrosis. Nat Nanotechnol. 2021, Apr;16(4):466\u201377. https:\/\/doi.org\/10.1038\/s41565-020-00836-6. Epub 2021 Jan 25. PMID: 33495618.","journal-title":"Nat Nanotechnol"},{"issue":"39","key":"7658_CR23","doi-asserted-by":"publisher","first-page":"34575","DOI":"10.1021\/acsnano.5c06003","volume":"19","author":"Z Sun","year":"2025","unstructured":"Sun Z, Zheng Q, Zhang Y, Bai C, Wang F, Yang P, Zhu D, Liu X, Li S, Liu D, Li R, He L, Yao J, Li X. Hydrogel loaded with Aminoethyl anisamide-modified exosomes attenuates hepatic fibrosis by targeting activated hepatic stellate cells. ACS Nano. 2025, Oct, 7;19(39):34575\u201395.","journal-title":"ACS Nano"},{"key":"7658_CR24","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000533857","volume":"13","author":"K Yasukawa","year":"2024","unstructured":"Yasukawa K, Shimizu A, Kubota K, Notake T, Hosoda K, Hayashi H, Soejima Y. Impact of liver fibrosis severity on oncological prognosis in hepatocellular carcinoma. Liver Cancer. 2024;13:150\u201360.","journal-title":"Liver Cancer"},{"key":"7658_CR25","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.1021\/acsnano.3c06107","volume":"18","author":"J Shinn","year":"2024","unstructured":"Shinn J, Park S, Lee S, Park N, Kim S, Hwang S, Moon JJ, Kwon Y, Lee Y. Antioxidative hyaluronic acid-bilirubin Nanomedicine targeting activated hepatic stellate cells for anti-hepatic-fibrosis therapy. ACS Nano. 2024;18:4704\u201316.","journal-title":"ACS Nano"},{"key":"7658_CR26","doi-asserted-by":"crossref","unstructured":"Ding Y, Luo Q, Que H, Wang N, Gong P, Gu J. Mesenchymal stem cell-derived exosomes: a promising therapeutic agent for the treatment of liver diseases. Int J Mol Sci. 2022;23.","DOI":"10.3390\/ijms231810972"},{"key":"7658_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/978-1-0716-3207-9_17","volume":"2669","author":"R Bansal","year":"2023","unstructured":"Bansal R, Poelstra K. Hepatic stellate cell targeting using peptide-modified biologicals. Methods Mol Biol. 2023;2669:269\u201384.","journal-title":"Methods Mol Biol"},{"key":"7658_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10495-019-01583-3","volume":"25","author":"R Li","year":"2020","unstructured":"Li R, Li Z, Feng Y, Yang H, Shi Q, Tao Z, Cheng J, Lu X. PDGFR\u03b2-targeted TRAIL specifically induces apoptosis of activated hepatic stellate cells and ameliorates liver fibrosis. Apoptosis. 2020;25:105\u201319.","journal-title":"Apoptosis"},{"key":"7658_CR29","doi-asserted-by":"publisher","first-page":"123656","DOI":"10.1016\/j.ijpharm.2023.123656","volume":"649","author":"K Haroon","year":"2024","unstructured":"Haroon K, Zheng H, Wu S, Liu Z, Tang Y, Yang GY, Liu Y, Zhang Z. Engineered exosomes mediated targeted delivery of neuroprotective peptide NR2B9c for the treatment of traumatic brain injury. Int J Pharm. 2024;649:123656.","journal-title":"Int J Pharm"},{"key":"7658_CR30","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jconrel.2012.05.014","volume":"161","author":"W Lu","year":"2012","unstructured":"Lu W, Xiong C, Zhang R, Shi L, Huang M, Zhang G, Song S, Huang Q, Liu GY, Li C. Receptor-mediated transcytosis: a mechanism for active extravascular transport of nanoparticles in solid tumors. J Control Release. 2012;161:959\u201366.","journal-title":"J Control Release"},{"key":"7658_CR31","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12951-022-01636-x","volume":"20","author":"Y Lin","year":"2022","unstructured":"Lin Y, Yan M, Bai Z, Xie Y, Ren L, Wei J, Zhu D, Wang H, Liu Y, Luo J, Li X. Huc-MSC-derived exosomes modified with the targeting peptide of aHscs for liver fibrosis therapy. J Nanobiotechnol. 2022;20:432.","journal-title":"J Nanobiotechnol"},{"key":"7658_CR32","doi-asserted-by":"publisher","first-page":"7747","DOI":"10.1021\/acsami.2c19269","volume":"15","author":"S Luo","year":"2023","unstructured":"Luo S, Yang Y, Zhao T, Zhang R, Fang C, Li Y, Zhang Z, Gong T. Albumin-based silibinin nanocrystals targeting activated hepatic stellate cells for liver fibrosis therapy. ACS Appl Mater Interface. 2023;15:7747\u201358.","journal-title":"ACS Appl Mater Interface"},{"key":"7658_CR33","doi-asserted-by":"publisher","first-page":"e2203315","DOI":"10.1002\/advs.202203315","volume":"10","author":"P Zhao","year":"2023","unstructured":"Zhao P, Sun T, Lyu C, Liang K, Niu Y, Zhang Y, Cao C, Xiang C, Du Y. Scar-degrading endothelial cells as a treatment for advanced liver fibrosis. Adv Sci (Weinh). 2023;10:e2203315.","journal-title":"Adv Sci (Weinh)"},{"key":"7658_CR34","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12967-019-2027-8","volume":"17","author":"H Chen","year":"2019","unstructured":"Chen H, Gan Q, Yang C, Peng X, Qin J, Qiu S, Jiang Y, Tu S, He Y, Li S, et al. A novel role of glutathione S-transferase A3 in inhibiting hepatic stellate cell activation and rat hepatic fibrosis. J Transl Med. 2019;17:280.","journal-title":"J Transl Med"},{"key":"7658_CR35","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1042\/CS20230533","volume":"138","author":"M Yamagata","year":"2024","unstructured":"Yamagata M, Tsuchishima M, Saito T, Tsutsumi M, George J. Therapeutic implication of human placental extract to prevent liver cirrhosis in rats with metabolic dysfunction-associated steatohepatitis. Clin Sci (Lond). 2024;138:327\u201349.","journal-title":"Clin Sci (Lond)"},{"key":"7658_CR36","doi-asserted-by":"publisher","first-page":"102210","DOI":"10.1016\/j.redox.2021.102210","volume":"49","author":"E Luengo","year":"2022","unstructured":"Luengo E, Trigo-Alonso P, Fern\u00e1ndez-Mend\u00edvil C, Nu\u00f1ez \u00c1, Campo MD, Porrero C, Garc\u00eda-Magro N, Negredo P, Senar S, S\u00e1nchez-Ramos C, et al. Implication of type 4 NADPH oxidase (NOX4) in tauopathy. Redox Biol. 2022;49:102210.","journal-title":"Redox Biol"},{"key":"7658_CR37","doi-asserted-by":"crossref","unstructured":"Kim Y, Park SY, Jung H, Noh YS, Lee JJ, Hong JY. Inhibition of NADPH oxidase 4 (NOX4) signaling attenuates tuberculous pleural fibrosis. J Clin Med. 2019;8.","DOI":"10.3390\/jcm8010116"},{"key":"7658_CR38","doi-asserted-by":"publisher","first-page":"101302","DOI":"10.1016\/j.redox.2019.101302","volume":"26","author":"M Kong","year":"2019","unstructured":"Kong M, Chen X, Lv F, Ren H, Fan Z, Qin H, Yu L, Shi X, Xu Y. Serum response factor (SRF) promotes ROS generation and hepatic stellate cell activation by epigenetically stimulating NCF1\/2 transcription. Redox Biol. 2019;26:101302.","journal-title":"Redox Biol"},{"key":"7658_CR39","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.cbi.2018.12.006","volume":"299","author":"Q Cheng","year":"2019","unstructured":"Cheng Q, Li C, Yang CF, Zhong YJ, Wu D, Shi L, Chen L, Li YW, Li L. Methyl ferulic acid attenuates liver fibrosis and hepatic stellate cell activation through the TGF-\u03b21\/Smad and NOX4\/ROS pathways. Chem Biol Interact. 2019;299:131\u201339.","journal-title":"Chem Biol Interact"},{"key":"7658_CR40","doi-asserted-by":"publisher","first-page":"4850","DOI":"10.2174\/092986712803341520","volume":"19","author":"V S\u00e1nchez-Valle","year":"2012","unstructured":"S\u00e1nchez-Valle V, Ch\u00e1vez-Tapia NC, Uribe M, M\u00e9ndez-S\u00e1nchez N. Role of oxidative stress and molecular changes in liver fibrosis: a review. Curr Med Chem. 2012;19:4850\u201360.","journal-title":"Curr Med Chem"},{"key":"7658_CR41","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.1038\/s41598-023-30582-3","volume":"13","author":"L Zhang","year":"2023","unstructured":"Zhang L, Liu C, Yin L, Huang C, Fan S. Mangiferin relieves CCl4-induced liver fibrosis in mice. Sci Rep. 2023;13:4172.","journal-title":"Sci Rep"},{"key":"7658_CR42","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.21037\/atm-22-5010","volume":"10","author":"A Niu","year":"2022","unstructured":"Niu A, Qi T. Diagnostic significance of serum type IV collagen (IVC) combined with aspartate aminotransferase (AST)\/alanine aminotransferase (ALT) ratio in liver fibrosis. Ann Transl Med. 2022;10:1310.","journal-title":"Ann Transl Med"},{"key":"7658_CR43","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s13238-012-2036-3","volume":"3","author":"J Hu","year":"2012","unstructured":"Hu J, Xu Y, Hao J, Wang S, Li C, Meng S. MiR-122 in hepatic function and liver diseases. Protein Cell. 2012;3:364\u201371.","journal-title":"Protein Cell"},{"key":"7658_CR44","doi-asserted-by":"crossref","unstructured":"Xiu AY, Ding Q, Li Z, Zhang CQ. Doxazosin attenuates liver fibrosis by inhibiting autophagy in hepatic stellate cells via activation of the PI3K\/Akt\/mTOR signaling pathway drug Des devel Ther. 2021;15:3643\u201359.","DOI":"10.2147\/DDDT.S317701"},{"issue":"Pt A","key":"7658_CR45","doi-asserted-by":"publisher","first-page":"109326","DOI":"10.1016\/j.intimp.2022.109326","volume":"113","author":"ZX Li","year":"2022","unstructured":"Li ZX, Sheng XD, Wang YL, Wen Lv X. Blocking P2X4 purinergic receptor attenuates alcohol-related liver fibrosis by inhibiting hepatic stellate cell activation through PI3K\/AKT signaling pathway. Int Immunopharmacol. 2022;113(Pt A):109326.","journal-title":"Int Immunopharmacol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07658-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07658-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07658-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:03:56Z","timestamp":1773407036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07658-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7658"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07658-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the First Hospital of Lanzhou University and was conducted according to the guidelines of the China Council on Animal Care and Use. Approval number: LDYYLL-2025\u201371; approval date: 07 February 2025.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors approved the final manuscript and the submission to this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"368"}}